Compare Screening and optimisation thresholds for Pre-operative anaemia across NICE, BSH, and ERAS. Built for Adults. Setting: Secondary. Urgency: Routine.
Clear thresholds help clinicians answer "when do I act?" for pre-operative anaemia, aligning expectations between NICE, BSH, and ERAS. Use this side-by-side view to decide when to refer, escalate, monitor, or initiate treatment.
| Guideline body | Position | Population & urgency |
|---|---|---|
| NICE | Position on Screening and optimisation thresholds for Pre-operative anaemia | Adults | Urgency: Routine | Setting: Secondary |
| BSH | Position on Screening and optimisation thresholds for Pre-operative anaemia | Adults | Urgency: Routine | Setting: Secondary |
| ERAS | Position on Screening and optimisation thresholds for Pre-operative anaemia | Adults | Urgency: Routine | Setting: Secondary |
Pre-operative anaemia affects approximately 30-40% of patients undergoing major surgery in the UK, with prevalence increasing to over 50% in elderly populations and those with chronic conditions. This common peri-operative challenge significantly impacts patient outcomes, with anaemic patients demonstrating 30-40% higher risk of post-operative complications, increased transfusion requirements, and longer hospital stays.
The key clinical challenge lies in balancing timely intervention against unnecessary treatment delays. Undetected or untreated pre-operative anaemia contributes to peri-operative morbidity, while over-aggressive management may delay essential surgery. Threshold decisions become critical when determining which patients require optimisation versus those who can proceed directly to surgery.
NICE adopts a population-health approach with broad screening recommendations, BSH provides haematology-specific guidance with detailed investigation pathways, while ERAS focuses on practical peri-operative optimisation within enhanced recovery frameworks. Understanding these philosophical differences helps clinicians apply the most appropriate guidance for individual patient scenarios.
| Guideline | Primary Focus | Typical Setting | Publication Date |
|---|---|---|---|
| NICE | Population health screening and standardised pathways | Secondary care with primary care integration | 2025 (NG243) |
| BSH | Haematological investigation and specialist management | Secondary/tertiary haematology services | 2025 |
| ERAS | Peri-operative optimisation and enhanced recovery | Secondary care surgical pathways | 2025 |
Use NICE as the default for general surgical populations in secondary care, BSH when complex haematological causes are suspected, and ERAS when working within established enhanced recovery programmes. Cross-reference between guidelines when managing patients with multiple comorbidities or when standard management proves ineffective.
| Threshold Parameter | NICE | BSH | ERAS | Notes |
|---|---|---|---|---|
| Haemoglobin screening threshold | All elective surgery patients | All patients 4-8 weeks pre-op | All major surgery patients | Major surgery defined as anticipated blood loss >500ml |
| Anaemia definition (men) | Hb <130 g/L | Hb <130 g/L | Hb <130 g/L | Consensus across all guidelines |
| Anaemia definition (women) | Hb <120 g/L | Hb <120 g/L | Hb <120 g/L | Consensus across all guidelines |
| Optimisation threshold | Hb <130 g/L (M), <120 g/L (F) | Hb <130 g/L (M), <120 g/L (F) | Hb <130 g/L (M), <120 g/L (F) | Initiate investigation and treatment |
| Time to surgery after detection | Minimum 3 weeks | 3-6 weeks | 2-4 weeks | ERAS allows faster turnaround in coordinated pathways |
NICE recommends baseline haemoglobin measurement at surgical referral or booking clinic visit. For patients with detected anaemia:
BSH emphasises comprehensive investigation alongside monitoring:
ERAS focuses on integrated pathway efficiency:
| Trigger | NICE | BSH | ERAS |
|---|---|---|---|
| Severe anaemia (Hb <80 g/L) | Urgent haematology referral | Immediate specialist review | Delay surgery, urgent optimisation |
| Failed oral iron therapy | Consider IV iron after 2 weeks | IV iron after 1 week failure | Direct to IV iron pathway |
| Complex anaemia (multifactorial) | Secondary care review | Haematology specialist management | Multi-disciplinary team input |
| Time-critical surgery | Expedited pathway | Consider pre-op transfusion | Integrated optimisation pathway |
| Elderly patients (>80 years) | Geriatric liaison | Comprehensive assessment | Enhanced recovery protocol |
| Cardiac comorbidities | Cardiology input if symptomatic | Formal cardiology assessment | Pre-op anaemia clinic review |
Patient: 68-year-old woman, BMI 28, scheduled for total knee replacement. Hb 118 g/L (lower limit of normal), normal MCV, ferritin 25 μg/L.
Analysis: NICE would recommend iron supplementation and repeat testing in 2 weeks. BSH would advocate full haematinic workup despite borderline values. ERAS would initiate protocol-driven IV iron therapy to ensure optimisation within 4-week window. The ERAS approach proves most appropriate given the fixed surgery date and minor deficiency.
Patient: 75-year-old man with CKD stage 3, type 2 diabetes, scheduled for colectomy. Hb 105 g/L, MCV 78 fL, ferritin 15 μg/L.
Analysis: NICE recommends secondary care management with iron therapy. BSH mandates haematology referral given multifactorial aetiology. ERAS suggests multi-disciplinary assessment including renal input. The BSH approach ensures comprehensive management of complex haematological issues.
Patient: 55-year-old woman with colorectal cancer, surgery scheduled in 10 days. Hb 95 g/L, recent chemotherapy.
Analysis: NICE suggests expedited pathway with possible delay. BSH recommends haematology review and potential transfusion. ERAS advocates immediate IV iron and erythropoietin stimulation. The ERAS protocol provides the most time-efficient solution for cancer surgery constraints.
While no validated risk prediction tool exists specifically for pre-operative anaemia outcomes, clinicians should consider several key factors when making threshold decisions:
Surgical Risk Stratification: Incorporate procedure-specific bleeding risk assessments. Major vascular, cardiac, and orthopaedic procedures carry higher anaemia-related complications.
Patient Comorbidity Burden: Use assessment tools like ASA physical status or Lee's Revised Cardiac Risk Index to contextualise anaemia management.
Functional Status Evaluation: Assess exercise tolerance and cardiopulmonary reserve. Patients with poor functional capacity tolerate anaemia less well.
BSH provides the most comprehensive framework for investigating anaemia aetiology, while ERAS integrates anaemia management within broader pre-operative risk assessment protocols.
Refer to the full guidelines for exact wording and local adaptations. This summary is for rapid orientation and multidisciplinary alignment.